Is SeaStar Medical Holding Corporation (ICU) a Buy, Sell, or Hold?
NASDAQ : ICU
SeaStar Medical Holding Corporation
$3.69 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 103.58K
- Market Capitalization
- $10.47M
- P/E Ratio
- -0.90
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $12.50
- Year Low
- $2.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.73
Company Overview
NASDAQ
Eric Schlorff
Biotechnology
Healthcare
ICU
17
US
USD
Liquidity Metrics
0.05
2.73
2.71
2.37
0.00
Sales & Valuation
$1.23M
7.29
19.77
-0.76
-0.35
Profitability
-$5.86
-$12.15M
-828.62%
-828.41%
-146.29%
-105.65%
P/E Metrics
-0.90
0.00
0.00
Analyst Price Target & Rating
$8.00
$8.00
$8.00
2/5
1 Analysts
-53.88%
Financial Health Scores
-20.35
2/9
$6.82M
$11.26M
$3.95M
-$11.96M
Key Metrics (TTM)
$1.46M
1.01
-0.12
2.73
-146.29%
-156.34%
-8.23%
-130.88%
-2395 days
Company Executives
| Name | Title |
|---|---|
| Bradford K. Towne | Controller & Principal Accounting Officer |
| Eric Schlorff | Chief Executive Officer, Treasurer, President & Executive Director |
| H. David Humes | Co-Founder & Scientific Advisor |
| Tim Varacek | Senior Vice President of Commercial & Business Operations |
| Sai Iyer | Senior Vice President of Medical Affairs & Research |
| Colonel Kevin Chung FACP | Chief Medical Officer |
| Tom Mullen | Vice President of Operations & Product Development |
| Michael Messinger | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About SeaStar Medical Holding Corporation (NASDAQ:ICU) Stock
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those wi ... th or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
2026-08-07 06:43:26
ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.
ICU Medical Q2 Earnings Call Highlights
2026-08-06 23:04:45
ICU Medical NASDAQ: ICUI reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
2026-08-06 16:05:00
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026.
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
2026-08-06 08:35:00
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and host a webcast and conference call to discuss its financial results and business progress.
ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
2026-07-23 08:30:00
SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2026 earnings release and conference call.
2026-07-14 08:34:00
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patients with acute kidney injury (AKI). AKI is a major driver of critical illness, prolonged hospital stays, and high mortality rates.
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
2026-06-23 08:25:00
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy
SeaStar Medical to Present at Upcoming Investor Summit Conference
2026-06-22 08:45:00
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time.
Frequently Asked Questions
-
What is the current SeaStar Medical Holding Corporation (ICU) stock price?
-
SeaStar Medical Holding Corporation(NASDAQ:ICU) stock price is $3.69 in the last trading session. During the trading session, ICU stock reached the peak price of $12.5 while $2.07 was the lowest point it dropped to. The percentage change in ICU stock occurred in the recent session was 0.0% while the dollar amount for the price change in ICU stock was $0.
-
ICU's industry and sector of operation?
-
The NASDAQ listed ICU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ICU?
-
Bradford K. Towne | Controller & Principal Accounting Officer
Eric Schlorff | Chief Executive Officer, Treasurer, President & Executive Director
H. David Humes | Co-Founder & Scientific Advisor
Tim Varacek | Senior Vice President of Commercial & Business Operations
Sai Iyer | Senior Vice President of Medical Affairs & Research -
How many employees does ICU have?
-
Number of ICU employees currently stands at 17. ICU operates from 3513 Brighton Boulevard, Denver, CO 80216, US.
-
Link for ICU official website?
-
Official Website of ICU is: https://www.seastarmedical.com
-
How do I contact ICU?
-
ICU could be contacted at phone #844 427 8100 and can also be accessed through its website. ICU operates from 3513 Brighton Boulevard, Denver, CO 80216, US.
-
How many shares of ICU are traded daily?
-
The average number of ICU shares traded daily for last 3 months was 103.58K.
-
What is the market cap of ICU currently?
-
The market value of ICU currently stands at $10.47M with its latest stock price at $3.69